Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents

Chemistry and Biology

Volumn 17, Issue 10, 2010, Pages 1111-1121

  Wang, Shudong ^a,b   Griffiths, Gary ^a   Midgley, Carol A ^a   Barnett, Anna L ^a   Cooper, Michael ^a   Grabarek, Joanna ^a   Ingram, Laura ^a   Jackson, Wayne ^a   Kontopidis, George ^a,c   McClue, Steven J ^a   McInnes, Campbell ^a,d   McLachlan, Janice ^a   Meades, Christopher ^a   Mezna, Mokdad ^a   Stuart, Iain ^a   Thomas, Mark P ^a   Zheleva, Daniella I ^a   Lane, David P ^a   Jackson, Robert C ^a   Glover, David M ^a   Blake, David G ^a   Fischer, Peter M ^a,b   more..

^a CYCLACEL LTD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF THESSALY   (Greece)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; PYRIMIDINE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LEUKEMIA; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA; MICE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 78049404246     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.07.016     Document Type: Article

References (53)

1. Y. Arima, M. Nitta, S. Kuninaka, D. Zhang, T. Fujiwara, Y. Taya, M. Nakao, and H. Saya Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria J. Biol. Chem. 280 2005 19166 19176
2. C. Barriere, D. Santamaria, A. Cerqueira, J. Galan, A. Martin, S. Ortega, M. Malumbres, P. Dubus, and M. Barbacid Mice thrive without Cdk4 and Cdk2 Mol. Oncol. 1 2007 72 83
3. S. Baumli, G. Lolli, E.D. Lowe, S. Troiani, L. Rusconi, A.N. Bullock, J.E. Debreczeni, S. Knapp, and L.N. Johnson The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation EMBO J. 27 2008 1907 1918
4. N.R. Brown, M.E. Noble, J.A. Endicott, and L.N. Johnson The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases Nat. Cell Biol. 1 1999 438 443
5. J.C. Byrd, T.S. Lin, J.T. Dalton, D. Wu, M.A. Phelps, B. Fischer, M. Moran, K.A. Blum, B. Rovin, and M. Brooker-McEldowney Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 109 2007 399 404
6. R. Chen, M.J. Keating, V. Gandhi, and W. Plunkett Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death Blood 106 2005 2513 2519
7. Y.-C. Cheng, and W.H. Prusoff Relation between the inhibition constant IK1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction Biochem. Pharmacol. 22 1973 3099 3108
8. S. Cory, D.C.S. Huang, and J.M. Adams The Bcl-2 family: roles in cell survival and oncogenesis Oncogene 22 2003 8590 8607
9. Z.N. Demidenko, and M.V. Blagosklonny Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor Cancer Res. 64 2004 3653 3660
10. P.M. Fischer, and A. Gianella-Borradori Recent progress in the discovery and development of CDK inhibitors Expert Opin. Investig. Drugs 14 2005 457 477
11. P. Fuentes-Prior, and G.S. Salvesen The protein structures that shape caspase activity, specificity, activation and inhibition Biochem. J. 384 2004 201 232
12. D.A. Gewirtz A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 57 1999 727 741
13. I. Gojo, B. Zhang, and R.G. Fenton The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1 Clin. Cancer Res. 8 2002 3527 3538
14. N.P. Gomes, G. Bjerke, B. Llorente, S.A. Szostek, B.M. Emerson, and J.M. Espinosa Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program Genes Dev. 20 2006 601 612
15. G. Griffiths, C. Midgley, J. Grabarek, M. Cooper, D. Glover, L. Ingram, W. Jackson, C. Meades, M. Mezna, and J. O'Boyle Identification and characterization of kinase inhibitors that inhibit CDK2, CDK7 and CDK 9 activities, induce p53 and result in reduced proliferation and induction of apoptosis of human tumor cells Proc. Am. Assoc. Cancer Res. 45 2004 837 Abs
16. G. Griffiths, F. Scaerou, C. Midgley, S. McClue, C. Tosh, W. Jackson, D. MacCallum, S. Wang, P. Fischer, D. Glover, and D. Zheleva Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2 Proc. Am. Assoc. Cancer Res. 49 2008 5644 Abs
17. J.W. Harper, and S.J. Elledge The role of Cdk7 in CAK function, a retro-retrospective Genes Dev. 12 1998 285 289
18. K. Haselsberger, D.C. Peterson, D.G. Thomas, and J.L. Darling Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma Anticancer Drugs 7 1996 331 338
19. Y. Hirose, and Y. Ohkuma Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression J. Biochem. 141 2007 601 608
20. D. Iglesias-Serret, M. Pique, J. Gil, G. Pons, and J.M. Lopez Transcriptional and translational control of Mcl-1 during apoptosis Arch. Biochem. Biophys. 417 2003 141 152
21. K.S. Joshi, M.J. Rathos, R.D. Joshi, M. Sivakumar, M. Mascarenhas, S. Kamble, B. Lal, and S. Sharma In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 Mol. Cancer Ther. 6 2007 918 925
22. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
23. M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig Participation of p53 protein in the cellular response to DNA damage Cancer Res. 51 1991 6304 6311
24. J.D. Khoury, L.J. Medeiros, G.Z. Rassidakis, T.J. McDonnell, L.V. Abruzzo, and R. Lai Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression J. Pathol. 199 2003 90 97
25. C. Koumenis, and A. Giaccia Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis Mol. Cell. Biol. 17 1997 7306 7316
26. M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf, P. Kallioniemi Olli, A. Shabaik, A. Vitiello, and D. Peehl Elevated expression of inhibitor of apoptosis proteins in prostate cancer Clin. Cancer Res. 9 2003 4914 4925
27. P. Liston, W.G. Fong, and R.G. Korneluk The inhibitors of apoptosis: there is more to life than Bcl2 Oncogene 22 2003 8568 8580
28. G. Lolli, E.D. Lowe, N.R. Brown, and L.N. Johnson The crystal structure of human CDK7 and its protein recognition properties Structure 12 2004 2067 2079
29. W. Lu, L. Chen, Y. Peng, and J. Chen Activation of p53 by roscovitine-mediated suppression of MDM2 expression Oncogene 20 2001 3206 3216
30. D.E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D.P. Lane, and S.R. Green Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 Cancer Res. 65 2005 5399 5407
31. J.C. Marsh, R.H. Shoemaker, and M. Suffness Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products Cancer Treat. Rep. 69 1985 683 685
32. C. McInnes, S. Wang, S. Anderson, J. O'Boyle, W. Jackson, G. Kontopidis, C. Meades, M. Mezna, M. Thomas, and G. Wood Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors Chem. Biol. 11 2004 525 534
33. D. Michael, and M. Oren The p53-Mdm2 module and the ubiquitin system Semin. Cancer Biol. 13 2003 49 58
34. A.A. Michels, V.T. Nguyen, A. Fraldi, V. Labas, M. Edwards, F. Bonnet, L. Lania, and O. Bensaude MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner Mol. Cell. Biol. 23 2003 4859 4869
35. C.A. Midgley, C.J. Fisher, J. Bartek, B. Vojtesek, D. Lane, and D.M. Barnes Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in Escherichia coli J. Cell Sci. 101 1992 183 189
36. R. Pinhero, P. Liaw, K. Bertens, and K. Yankulov Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II Eur. J. Biochem. 271 2004 1004 1014
37. D.H. Price P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II Mol. Cell. Biol. 20 2000 2629 2634
38. S.K. Radhakrishnan, and A.L. Gartel A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity Cancer Res. 66 2006 3264 3270
39. Y. Ramanathan, S.M. Rajpara, S.M. Reza, E. Lees, S. Shuman, M.B. Mathews, and T. Pe'ery Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences J. Biol. Chem. 276 2001 10913 10920
40. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J. Biol. Chem. 273 1998 5858 5868
41. A.D. Schimmer Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice Cancer Res. 64 2004 7183 7190
42. G.I. Shapiro, and J.W. Harper Anticancer drug targets: cell cycle and checkpoint control J. Clin. Invest. 104 1999 1645 1653
43. R.J. Sims, S.S. Mandal, and D. Reinberg Recent highlights of RNA-polymerase-II-mediated transcription Curr. Opin. Cell Biol. 16 2004 263 271
44. L. Song, D. Coppola, S. Livingston, D. Cress, and E.B. Haura Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells Cancer Biol. Ther. 4 2005 267 276
45. S. Wang, and P.M. Fischer Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol. Sci. 29 2008 302 313
46. S. Wang, C. Meades, G. Wood, A. Osnowski, S. Anderson, R. Yuill, M. Thomas, M. Mezna, W. Jackson, and C. Midgley 2-anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-Ray crystallography, and biological activity J. Med. Chem. 47 2004 1662 1675
47. S. Wang, G. Wood, C. Meades, G. Griffiths, C. Midgley, I. McNae, C. McInnes, S. Anderson, W. Jackson, and M. Mezna Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibitors Bioorg. Med. Chem. Lett. 14 2004 4237 4240 (Pubitemid 38916943)
48. S. Wang, G. Griffiths, C. Midgley, C. Meades, J. O'Boyle, D. Gibson, G. Wood, J. Grabarek, M. Cooper, and M. Mezna Discovery and evaluation of CDK transcriptional inhibitors as anti-cancer agents Proc. Am. Assoc. Cancer Res. 46 2005 Abs. LB-110
49. S. Wang, C.A. Midgley, F. Scaeërou, J.B. Grabarek, G. Griffiths, W. Jackson, G. Kontopidis, S.J. McClue, C. McInnes, and C. Meades Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors J. Med. Chem. 53 2010 4367 4378
50. S.Y. Wu, I. McNae, G. Kontopidis, S.J. McClue, C. McInnes, K.J. Stewart, S. Wang, D.I. Zheleva, H. Marriage, and D.P. Lane Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop Structure 11 2003 399 410
51. U. Zangemeister-Wittke, and H.-U. Simon An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy Cell Cycle 3 2004 1121 1123
52. C. Zhang, K. Lundgren, Z. Yan, M.E. Arango, S. Price, A. Huber, J. Higgins, G. Troche, J. Skaptason, and T. Koudriakova Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy Mol. Cancer Ther. 7 2008 818 828
53. M. Zhou, M.A. Halanski, M.F. Radonovich, F. Kashanchi, J. Peng, D.H. Price, and J.N. Brady Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription Mol. Cell. Biol. 20 2000 5077 5086